<SEC-DOCUMENT>0000919574-25-004068.txt : 20250711
<SEC-HEADER>0000919574-25-004068.hdr.sgml : 20250711
<ACCEPTANCE-DATETIME>20250711123010
ACCESSION NUMBER:		0000919574-25-004068
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20250711
DATE AS OF CHANGE:		20250711

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jasper Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001788028
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				842984849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91228
		FILM NUMBER:		251118236

	BUSINESS ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		6505491400

	MAIL ADDRESS:	
		STREET 1:		2200 BRIDGE PKWY SUITE #102
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Amplitude Healthcare Acquisition Corp
		DATE OF NAME CHANGE:	20190912

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KINGDON CAPITAL MANAGEMENT, L.L.C.
		CENTRAL INDEX KEY:			0001000097
		ORGANIZATION NAME:           	
		EIN:				134015739
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		152 WEST 57TH STREET
		STREET 2:		50TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		212-333-0100

	MAIL ADDRESS:	
		STREET 1:		152 WEST 57TH STREET
		STREET 2:		50TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KINGDON CAPITAL MANAGEMENT LLC
		DATE OF NAME CHANGE:	19980914

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	KINGDON CAPITAL MANAGEMENT CORP
		DATE OF NAME CHANGE:	19960408
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: KINGDON CAPITAL MANAGEMENT, L.L.C. -->
          <cik>0001000097</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Voting Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>07/03/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001788028</issuerCik>
        <issuerName>Jasper Therapeutics, Inc.</issuerName>
        <issuerCusip>471871202</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>2200 Bridge Pkwy Suite #102</com:street1>
          <com:city>Redwood City</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94065</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>KINGDON CAPITAL MANAGEMENT, L.L.C.</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>765000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>765000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>765000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.1</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Mark Kingdon</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>765000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>765000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>765000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.1</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Jasper Therapeutics, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>2200 Bridge Parkway, Suite #102, Redwood City, CA 94065, United States of America</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Kingdon Capital Management, L.L.C.
Mark Kingdon</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Kingdon Capital Management, L.L.C.
152 West 57th Street, 50th Floor
New York, New York 10019
United States of America

Mark Kingdon
c/o Kingdon Capital Management, L.L.C.
152 West 57th Street, 50th Floor
New York, New York 10019
United States of America</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Kingdon Capital Management, L.L.C. - Delaware
Mark Kingdon - United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Kingdon Capital Management, L.L.C. - 765,000
Mark Kingdon - 765,000</amountBeneficiallyOwned>
        <classPercent>Kingdon Capital Management, L.L.C. - 5.1%
Mark Kingdon - 5.1%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Kingdon Capital Management, L.L.C. - 0
Mark Kingdon - 0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Kingdon Capital Management, L.L.C. - 765,000
Mark Kingdon - 765,000</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Kingdon Capital Management, L.L.C. - 0
Mark Kingdon - 0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Kingdon Capital Management, L.L.C. - 765,000
Mark Kingdon - 765,000</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>All of the securities reported in this Schedule 13G are directly owned by advisory clients of Kingdon Capital Management, L.L.C. None of those advisory clients may be deemed to beneficially own more than 5% of the Voting Common Stock, par value $0.0001 per share.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>N</notApplicableFlag>
        <subsidiaryIdentificationAndClassification>Please see Exhibit B attached hereto.</subsidiaryIdentificationAndClassification>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Exhibit A - Joint Filing Agreement

Exhibit B - Control Person Identification</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>KINGDON CAPITAL MANAGEMENT, L.L.C.</reportingPersonName>
      <signatureDetails>
        <signature>By: /s/ Richard Weinstein</signature>
        <title>Richard Weinstein / Chief Operating Officer &amp; General Counsel</title>
        <date>07/11/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Mark Kingdon</reportingPersonName>
      <signatureDetails>
        <signature>By: /s/ Mark Kingdon</signature>
        <title>Mark Kingdon</title>
        <date>07/11/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>* Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.</signatureComments>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>d11848978_ex99-a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><U>Exhibit A</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><U>JOINT FILING AGREEMENT</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned agree that
this Schedule 13G dated July 11, 2025 relating to the Voting Common Stock, par value $0.0001 per share, of Jasper Therapeutics, Inc. shall
be filed on behalf of the undersigned.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%; padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 52%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">KINGDON CAPITAL MANAGEMENT, L.L.C.</P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">By: /s/ Richard Weinstein</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 24pt"><FONT STYLE="font-size: 11pt">Name: Richard Weinstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 24pt"><FONT STYLE="font-size: 11pt">Title:&nbsp;&nbsp;&nbsp;Chief Operating Officer &amp; General Counsel</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">MARK KINGDON</P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">By: /s/ Mark Kingdon</P></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>d11848978_ex99-b.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 6.75pt 6pt 0; text-align: right">&nbsp;<U>Exhibit <FONT STYLE="letter-spacing: -0.5pt">B</FONT></U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 4.7pt 136pt 0 137.05pt; text-align: center">CONTROL PERSON <FONT STYLE="letter-spacing: -0.1pt">IDENTIFICATION</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 2.75pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt/95% Times New Roman, Times, Serif; margin: 0 0 0 8.2pt">Kingdon Capital Management, L.L.C. is the relevant entity
for which Mark Kingdon may be considered a control <FONT STYLE="letter-spacing: -0.1pt">person.</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
